[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100504953":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":32,"locations":40,"responsibleParty":68,"collaborators":70,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":18,"eligibilityCriteria":86,"healthyVolunteers":82,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":18,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":104,"overallStatus":43,"whyStopped":18,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Zealand University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention","EXPERIMENTAL","An invitation to a liver stiffness measurement (Transient Elastography), to blood sampling and a leaflet on alcohol-related disease.",[13],"Diagnostic Test: Transient Elastography",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","NO_INTERVENTION","An invitation to screening by blood sampling with Fib-4",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DIAGNOSTIC_TEST","Transient Elastography","One transient elastography 1-2 weeks after randomization",[9],[26,27],"Fibroscan","Liver stiffness measurement",[29],{"name":30,"affiliation":5,"role":31},"Gro Askgaard, PHD","PRINCIPAL_INVESTIGATOR",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":18,"email":37},"Pernille Dahlin, MD","CONTACT","+45 30291114","pedah@regionsjaelland.dk",{"name":30,"role":35,"phone":18,"phoneExt":18,"email":39},"gras@regionsjaelland.dk",[41,57],{"facility":42,"status":43,"city":44,"state":18,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Novavi Køge","RECRUITING","Køge","4600","Denmark","DK",{"type":49,"coordinates":50},"Point",[51,52],12.18214,55.45802,{"lat":52,"lon":51},[55],{"name":34,"role":35,"phone":56,"phoneExt":18,"email":37},"30291114",{"facility":58,"status":43,"city":59,"state":18,"zip":60,"country":46,"countryCode":47,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Novavi Roskilde","Roskilde","4000",{"type":49,"coordinates":62},[63,64],12.08035,55.64152,{"lat":64,"lon":63},[67],{"name":34,"role":35,"phone":56,"phoneExt":18,"email":37},{"type":69,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[71,74,76,78],{"name":72,"class":73},"Novavi","UNKNOWN",{"name":75,"class":6},"Aarhus University Hospital",{"name":77,"class":6},"Frederiksberg University Hospital",{"name":79,"class":6},"University of Copenhagen","100504953","the-liver-care-trial-100504953",false,"NCT05855031","The Liver Care Trial","The Liver Care Trial: Screening for Liver Disease in Individuals Attending Treatment for Alcohol Use Disorder - a Randomized Controlled Study","Inclusion Criteria:\n\n* Attending outpatient treatment for alcohol use disorder (international classification of disease version 10: F102: alcohol dependence or F101: harmful alcohol use) at Novavi Køge or Novavi Roskilde\n* Informed written consent\n\nExclusion Criteria:\n\n* Not speaking Danish or English\n* Severe liver disease (known by the participant)","ALL","18 Years","110 Years",{"count":91,"type":92},408,"ESTIMATED","INTERVENTIONAL",[95],"NA","The goal of this clinical trial is to evaluate the efficacy of screening for liver disease with liver stiffness measurement on abstinence or light consumption after 6 months in individuals who are receiving treatment for alcohol use disorder and without a history of liver disease. The investigators will conduct a randomized controlled trial with concealed allocation comparing A) an invitation to a liver stiffness measurement, blood sampling and leaflet on alcohol-related disease (intervention) with B) an invitation to blood sampling (control). The primary outcome is 'abstinence or light consumption' (≤ 10 units\u002Fweek) throughout the last months, and assessed 6 months after randomization.",[98,99,100,101,102,103],"Alcoholic Liver Disease","Alcohol Use Disorder","Alcohol Abuse","Alcoholism","Fibrosis, Liver","Alcohol-Related Disorders",[105,26,27,106],"Screening","abstinence","2023-05-15",{"date":109,"type":110},"2023-05-17","ACTUAL",{"date":112,"type":110},"2023-05-08",{"date":114,"type":92},"2027-05-01",{"name":5,"class":6},2]